Upstream Bio (NASDAQ:UPB) Trading Down 10.3% – Should You Sell?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price was down 10.3% on Thursday . The company traded as low as $13.42 and last traded at $13.1760. Approximately 804,962 shares were traded during trading, a decline of 12% from the average daily volume of 910,805 shares. The stock had previously closed at $14.69.

Analyst Ratings Changes

UPB has been the topic of several recent research reports. Lifesci Capital began coverage on Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, Evercore assumed coverage on shares of Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Upstream Bio presently has an average rating of “Moderate Buy” and an average target price of $45.25.

Upstream Bio Stock Performance

The firm has a 50-day moving average price of $28.25 and a two-hundred day moving average price of $23.18. The firm has a market cap of $472.85 million, a price-to-earnings ratio of -4.65 and a beta of 1.90.

Institutional Trading of Upstream Bio

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its position in shares of Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after buying an additional 985 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Upstream Bio during the fourth quarter worth about $29,000. Torren Management LLC purchased a new position in shares of Upstream Bio during the fourth quarter worth about $30,000. JPMorgan Chase & Co. lifted its holdings in shares of Upstream Bio by 8.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after purchasing an additional 1,275 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Upstream Bio by 2.8% in the 3rd quarter. Rhumbline Advisers now owns 49,406 shares of the company’s stock valued at $929,000 after purchasing an additional 1,340 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.